Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Current Leases (2017 - 2024)

Historic Current Leases for Astrazeneca (AZNCF) over the last 7 years, with Q4 2024 value amounting to $339.0 million.

  • Astrazeneca's Current Leases rose 2509.23% to $339.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $339.0 million, marking a year-over-year increase of 2509.23%. This contributed to the annual value of $339.0 million for FY2024, which is 2509.23% up from last year.
  • Latest data reveals that Astrazeneca reported Current Leases of $339.0 million as of Q4 2024, which was up 2509.23% from $271.0 million recorded in Q4 2023.
  • Over the past 5 years, Astrazeneca's Current Leases peaked at $339.0 million during Q4 2024, and registered a low of $192.0 million during Q4 2020.
  • For the 5-year period, Astrazeneca's Current Leases averaged around $252.6 million, with its median value being $233.0 million (2021).
  • As far as peak fluctuations go, Astrazeneca's Current Leases plummeted by 214.59% in 2022, and later soared by 2509.23% in 2024.
  • Quarter analysis of 5 years shows Astrazeneca's Current Leases stood at $192.0 million in 2020, then grew by 21.35% to $233.0 million in 2021, then dropped by 2.15% to $228.0 million in 2022, then rose by 18.86% to $271.0 million in 2023, then grew by 25.09% to $339.0 million in 2024.
  • Its last three reported values are $339.0 million in Q4 2024, $271.0 million for Q4 2023, and $228.0 million during Q4 2022.